<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029536</url>
  </required_header>
  <id_info>
    <org_study_id>2001P001408</org_study_id>
    <secondary_id>NINDS NS39466</secondary_id>
    <secondary_id>CRC</secondary_id>
    <nct_id>NCT00029536</nct_id>
  </id_info>
  <brief_title>Progesterone vs Placebo Therapy for Women With Epilepsy</brief_title>
  <official_title>Phase 3 Study of Progesterone vs Placebo Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montreal Neurological Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minnesota Comprehensive Epilepsy Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation was to determine if cyclic adjunctive progesterone
      supplement is superior to placebo in the treatment of intractable seizures in women with and
      without catamenial epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6-month study. The first 3 months will gather baseline information on seizures,
      antiepileptic drug levels , menstrual cycles, hormone levels, emotional function, and quality
      of life. The second 3 months will assess the effects of treatment on these parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This was a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Randomization was carried out separately for women with and without catamenial epilepsy, 2:1 to progesterone or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency</measure>
    <time_frame>9 years</time_frame>
    <description>Percent of women who show a greater than 50% decline in average daily seizure frequency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Women Who Show a &gt;50% Decline in Average Daily Seizure Frequency for the Most Severe Seizure Type.</measure>
    <time_frame>9 years</time_frame>
    <description>Percent of women who show a &gt;50% decline in average daily seizure frequency for the most severe seizure type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency for Secondary Generalized, Complex Partial and Simple Partial Seizures Considered Separately</measure>
    <time_frame>9 years</time_frame>
    <description>Percentage of women who show a greater than 50% decline in average daily seizure frequency for secondary generalized, complex partial and simple partial seizures considered separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Progesterone Levels in Subjects at Baseline and After Treatment.</measure>
    <time_frame>9 years</time_frame>
    <description>Changes in serum progesterone levels in subjects at baseline and after treatment with progesterone or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Levels of Antiepileptic Drugs on Progesterone and Placebo for Subjects With Catamenial and Non-catamenial Epilepsy.</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Catamenial Epilepsy: Progesterone Lozenges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catamenial Epilepsy: Placebo Lozenges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Noncatamenial Epilespy:Progesterone Lozenges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Noncatamenial Epilespy: Placebo Lozenges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Progesterone Lozenges</intervention_name>
    <description>200mg Progesterone Lozenges</description>
    <arm_group_label>Catamenial Epilepsy: Progesterone Lozenges</arm_group_label>
    <arm_group_label>Noncatamenial Epilespy:Progesterone Lozenges</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matched Placebo Lozenges</intervention_name>
    <description>Matched Placebo Lozenges</description>
    <arm_group_label>Catamenial Epilepsy: Placebo Lozenges</arm_group_label>
    <arm_group_label>Noncatamenial Epilespy: Placebo Lozenges</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          1. Subject must be between the ages of 13 and 45.

          2. Subject must have a history of seizures (documented by EEG).

          3. Subject must have had at least 2 seizures or auras per month during the past 3 months.

          4. Subject must be on stable antiepileptic drug therapy for at least 2 months.

          5. Subject must have cycle intervals between 21 and 35 days during 6 months prior to
             entry.

        EXCLUSION:

          1. Subject that is pregnant or lactating.

          2. Subject that is on major tranquilizers, antidepressant medications, or reproductive
             hormones.

          3. Subject that is unable to document seizures.

          4. Subject that has progressive neurological or systemic disorder or &gt; 2-fold elevation
             in liver enzyme levels
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew G Herzog, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California, Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center; Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Harvard Neuroendocrine Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MINCEP Epilepsy Care</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital- Weill Medical College of Cornell University, Comprehensive Epilepsy Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital, Comprehensive Epilepsy Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology. 1995 Sep;45(9):1660-2.</citation>
    <PMID>7675223</PMID>
  </reference>
  <reference>
    <citation>Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999 Jun 10;52(9):1917-8.</citation>
    <PMID>10371551</PMID>
  </reference>
  <reference>
    <citation>Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997 Oct;38(10):1082-8.</citation>
    <PMID>9579954</PMID>
  </reference>
  <results_reference>
    <citation>Herzog AG, Harden CL, Liporace J, Pennell P, Schomer DL, Sperling M, Fowler K, Nikolov B, Shuman S, Newman M. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol. 2004 Sep;56(3):431-4.</citation>
    <PMID>15349872</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2002</study_first_submitted>
  <study_first_submitted_qc>January 15, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2002</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>June 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Herzog</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Seizure</keyword>
  <keyword>Hormone</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Catamenial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Catamenial Epilepsy: Progesterone Lozenges</title>
          <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
        </group>
        <group group_id="P2">
          <title>Catamenial Epilepsy: Placebo Lozenges</title>
          <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
        </group>
        <group group_id="P3">
          <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
          <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
        </group>
        <group group_id="P4">
          <title>Noncatamenial Epilespy: Placebo Lozenges</title>
          <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Catamenial Epilepsy: Progesterone Lozenges</title>
          <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
        </group>
        <group group_id="B2">
          <title>Catamenial Epilepsy: Placebo Lozenges</title>
          <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
        </group>
        <group group_id="B3">
          <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
          <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
        </group>
        <group group_id="B4">
          <title>Noncatamenial Epilespy: Placebo Lozenges</title>
          <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="105"/>
            <count group_id="B4" value="59"/>
            <count group_id="B5" value="294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" spread="8.68"/>
                    <measurement group_id="B2" value="32.31" spread="8.5"/>
                    <measurement group_id="B3" value="30.71" spread="8.16"/>
                    <measurement group_id="B4" value="32.42" spread="7.87"/>
                    <measurement group_id="B5" value="31.71" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency</title>
        <description>Percent of women who show a greater than 50% decline in average daily seizure frequency</description>
        <time_frame>9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catamenial Epilepsy: Progesterone Lozenges</title>
            <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O2">
            <title>Catamenial Epilepsy: Placebo Lozenges</title>
            <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
          </group>
          <group group_id="O3">
            <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
            <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O4">
            <title>Noncatamenial Epilespy: Placebo Lozenges</title>
            <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency</title>
          <description>Percent of women who show a greater than 50% decline in average daily seizure frequency</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="20.2"/>
                    <measurement group_id="O4" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Women Who Show a &gt;50% Decline in Average Daily Seizure Frequency for the Most Severe Seizure Type.</title>
        <description>Percent of women who show a &gt;50% decline in average daily seizure frequency for the most severe seizure type.</description>
        <time_frame>9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catamenial Epilepsy: Progesterone Lozenges</title>
            <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O2">
            <title>Catamenial Epilepsy: Placebo Lozenges</title>
            <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
          </group>
          <group group_id="O3">
            <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
            <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O4">
            <title>Noncatamenial Epilespy: Placebo Lozenges</title>
            <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Women Who Show a &gt;50% Decline in Average Daily Seizure Frequency for the Most Severe Seizure Type.</title>
          <description>Percent of women who show a &gt;50% decline in average daily seizure frequency for the most severe seizure type.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency for Secondary Generalized, Complex Partial and Simple Partial Seizures Considered Separately</title>
        <description>Percentage of women who show a greater than 50% decline in average daily seizure frequency for secondary generalized, complex partial and simple partial seizures considered separately</description>
        <time_frame>9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catamenial Epilepsy: Progesterone Lozenges</title>
            <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O2">
            <title>Catamenial Epilepsy: Placebo Lozenges</title>
            <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
          </group>
          <group group_id="O3">
            <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
            <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O4">
            <title>Noncatamenial Epilespy: Placebo Lozenges</title>
            <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Women Who Show a Greater Than 50% Decline in Average Daily Seizure Frequency for Secondary Generalized, Complex Partial and Simple Partial Seizures Considered Separately</title>
          <description>Percentage of women who show a greater than 50% decline in average daily seizure frequency for secondary generalized, complex partial and simple partial seizures considered separately</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SGMS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.39"/>
                    <measurement group_id="O2" value="29.41"/>
                    <measurement group_id="O3" value="21.21"/>
                    <measurement group_id="O4" value="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.68"/>
                    <measurement group_id="O2" value="18.60"/>
                    <measurement group_id="O3" value="21.21"/>
                    <measurement group_id="O4" value="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.12"/>
                    <measurement group_id="O2" value="41.21"/>
                    <measurement group_id="O3" value="42.22"/>
                    <measurement group_id="O4" value="31.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Progesterone Levels in Subjects at Baseline and After Treatment.</title>
        <description>Changes in serum progesterone levels in subjects at baseline and after treatment with progesterone or placebo.</description>
        <time_frame>9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Catamenial Epilepsy: Progesterone Lozenges</title>
            <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O2">
            <title>Catamenial Epilepsy: Placebo Lozenges</title>
            <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
          </group>
          <group group_id="O3">
            <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
            <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O4">
            <title>Noncatamenial Epilespy: Placebo Lozenges</title>
            <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Progesterone Levels in Subjects at Baseline and After Treatment.</title>
          <description>Changes in serum progesterone levels in subjects at baseline and after treatment with progesterone or placebo.</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="5.8" upper_limit="12.0"/>
                    <measurement group_id="O2" value="9.1" lower_limit="5.9" upper_limit="12.9"/>
                    <measurement group_id="O3" value="10.8" lower_limit="7.3" upper_limit="13.1"/>
                    <measurement group_id="O4" value="9.1" lower_limit="6.5" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="28.9" upper_limit="87.9"/>
                    <measurement group_id="O2" value="9.2" lower_limit="5.1" upper_limit="13.7"/>
                    <measurement group_id="O3" value="49.6" lower_limit="27.0" upper_limit="88.25"/>
                    <measurement group_id="O4" value="12.0" lower_limit="7.5" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Levels of Antiepileptic Drugs on Progesterone and Placebo for Subjects With Catamenial and Non-catamenial Epilepsy.</title>
        <time_frame>9 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone Lozenges</title>
            <description>Subjects with catamenial and Non-Catamential epilepsy who received 200 mg progesterone lozenges</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>Subjects with catamenial and non-Catamenial epilepsy who received matched placebo lozenges</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Levels of Antiepileptic Drugs on Progesterone and Placebo for Subjects With Catamenial and Non-catamenial Epilepsy.</title>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbamazepine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="2.5"/>
                    <measurement group_id="O2" value="9.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levitracetam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="17.1"/>
                    <measurement group_id="O2" value="22.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lamotrigine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="8.2"/>
                    <measurement group_id="O2" value="8.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topirimate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="6.9"/>
                    <measurement group_id="O2" value="9.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phenytoin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="6.5"/>
                    <measurement group_id="O2" value="17.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Catamenial Epilepsy: Progesterone Lozenges</title>
          <description>Subjects with catamenial epilepsy received 200 mg progesterone lozenges</description>
        </group>
        <group group_id="E2">
          <title>Catamenial Epilepsy: Placebo Lozenges</title>
          <description>Subjects with catamenial epilepsy received matched placebo lozenges</description>
        </group>
        <group group_id="E3">
          <title>Noncatamenial Epilespy:Progesterone Lozenges</title>
          <description>Subjects without catamenial epilepsy received 200 mg progesterone lozenges</description>
        </group>
        <group group_id="E4">
          <title>Noncatamenial Epilespy: Placebo Lozenges</title>
          <description>Subjects without catamenial epilepsy received matched placebo lozenges</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>SUDEP</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Seizures</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysepepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew G. Herzog</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>781-431-0277</phone>
      <email>aherzog@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

